TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00723294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryosurgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT03487666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human programmed death receptor-1 (PD-1) antibody currently approved in different diseases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human programmed death receptor-1 (PD-1) antibody currently approved in different diseases.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects
Study: NCT03554187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic periodontal Debridement, with appropriate device
Description: Dental procedure that includes therapeutic interventions such as scaling to remove calculus and all soft deposits, root planing to eliminate subgingival calculus and smooth the tooth surface, and root débridement to eliminate subgingival biofilm and lightly mineralized deposits.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasonic periodontal Debridement, with appropriate device
Description: Dental procedure that includes therapeutic interventions such as scaling to remove calculus and all soft deposits, root planing to eliminate subgingival calculus and smooth the tooth surface, and root débridement to eliminate subgingival biofilm and lightly mineralized deposits.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Analyzes of periodontopathogenic bacteria
Description: Collection of plaque, to analyze the bacteria in the pocket

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Analyzes of periodontopathogenic bacteria
Description: Collection of plaque, to analyze the bacteria in the pocket

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: IL1B test
Description: susceptibility to periodontal disease (scratch swab onto the tongue) (no invasive)

Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: IL1B test
Description: susceptibility to periodontal disease (scratch swab onto the tongue) (no invasive)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salivary Sampling
Description: Salivette to chew. To analyse salivary microbiota

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Salivary Sampling
Description: Salivette to chew. To analyse salivary microbiota

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Halitosis measure
Description: With appropriate device : halimeter

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Halitosis measure
Description: With appropriate device : halimeter
Study: NCT03095443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy - Personalized Playlist
Description: Participant receives personalized playlist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Therapy - Standard Playlist
Description: Participant receives a standard low beats per minute playlist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participant receives an audio-book.
Study: NCT04069299

Intervention type: DRUG
Intervention: 68Ga-DOTATATE
Description: The NETspot kit is 2 vials, Vial 1 contains 40 mcg dotatate, 5 mcg 1,10phenanthroline; 6mcg gentisic acid and 20 mg mannitol. Vial 2 contains 60 mg formic acid, 56.5 mg sodium hydroxide and water for injection

Intervention type: DIAGNOSTIC_TEST
Intervention: Positron Emission Tomography (PET) Scan
Description: PET scan is an imaging test using radioactive tracers.
Study: NCT03993873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elzovantinib (TPX-0022)
Description: Oral elzovantinib (TPX-0022) capsules
Study: NCT02594527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volunteer-led physical activity session
Description: Participants will be encouraged by volunteers to walk or perform chair-based exercises during their stay in hospital
Study: NCT01576315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole/voriconazole
Description: The two treatments will be administered orally for 6 months One doage of treatment permitted based on plasma levels will be performed after two weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole/voriconazole
Description: The two treatments will be administered orally for 6 months One doage of treatment permitted based on plasma levels will be performed after two weeks of treatment.
Study: NCT05696041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static strength training program or/and Dynamic strength training program of the hand
Description: Four of the five exercises included in the static or dynamic training program were based on holding the weight over the edge of the table and maintaining the position for 10 seconds, then resting briefly and changing to the next position. The training was performed in the following assumed positions, pronation, supination, radial and ulnar position. In the fifth and final exercise, you would squeeze an exercise ball as hard as possible without pain. The starting weight was 0.5 kilogram, and each exercise (1-4) was performed in three sets in the first week. The training increased by one set per week for up to eight sets/week if pain or paresthesia got worsened. If the training worked, the OT and the subject could choose to increase the weight to 1 kilogram and start over with three sets/day and gradually increase the training or switch to a dynamic training program.
Study: NCT04093128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: herbal tea intervention
Description: herbal tea intervention for 7 weeks
Study: NCT02788656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Hemodynamic Monitor
Description: The CardioMEMS device is an implantable pulmonary artery pressure monitor that is FDA-approved for use in patients with symptomatic heart failure and previous heart failure hospitalization. Patients eligible for this study are those with an already implanted CardioMEMS device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Hemodynamic Monitor
Description: The CardioMEMS device is an implantable pulmonary artery pressure monitor that is FDA-approved for use in patients with symptomatic heart failure and previous heart failure hospitalization. Patients eligible for this study are those with an already implanted CardioMEMS device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin-Converting Enzyme Inhibitor
Description: Conventional, guideline-directed therapy for heart failure and reduced ejection fraction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin II Type 1 Receptor Blocker
Description: Conventional, guideline-directed therapy for heart failure and reduced ejection fraction in ACE-inhibitor intolerant patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: Angiotensin-neprilysin inhibitor that is now FDA-approved and guideline-directed therapy for patients with symptomatic heart failure and reduced ejection fraction despite treatment with an ACE-inhibitor/Angiotensin-Receptor Blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sacubitril/valsartan
Description: Angiotensin-neprilysin inhibitor that is now FDA-approved and guideline-directed therapy for patients with symptomatic heart failure and reduced ejection fraction despite treatment with an ACE-inhibitor/Angiotensin-Receptor Blocker
Study: NCT02947711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: 2 x 50 mg capsules, once daily on Day 1 and Day 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem ER
Description: 1 x 300 mg capsule, once daily on Days 7 through 24
Study: NCT02263885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial System
Description: Transcranial MRgFUS
Study: NCT03215979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet enriched plasma administration
Description: It is a blinded administration of platelet enriched plasma in the temporal fascia used to cover the auricular reconstruction frame, during the second stage of the procedure. The use of platelet enriched plasma is focused to improve the integration rate of the full-thickness split skin graft
Study: NCT01386840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Severe Pneumonia - Home Management
Description: For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers.
Study: NCT03454932

Intervention type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Intervention: Blood sampling

Intervention type: OTHER
Intervention: Blood sampling
Study: NCT00917189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenging Our Minds Program
Description: A computerized cognitive intervention that provides training in attention, memory, and executive function
Study: NCT00765661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tacro™)
Description: The initial dose at 0.14 mg/kg (daily dose for African-American is 0.17 mg/kg), oral in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target tacrolimus trough level of 7 - 20 ng/mL for (PK) phase of the study (through Study Day 14). Post PK maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other Names:~Tacrolimus modified-release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Prograf® capsules, twice daily: Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus
Study: NCT00227747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04189328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant placement using magnifying loupes and microsurgical instruments
Description: microsurgical dental implant placement employin splt finger technique by Misch

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: macrosurgical dental implant placement
Description: macrosurgical placement of single dental implants
Study: NCT03569969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: device: Tympanoplasty with Membrane Amniotic
Description: amniotic membrane Tympanoplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tympanoplasty With Autologous Fascia
Description: Autologous Temporalis fascia Tympanoplasty
Study: NCT03623646

Intervention type: DRUG
Group type: OTHER
Intervention: Chemoradiotherapy arm
Description: Radiation Therapy in combination with Chemotherapy (Cisplatin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy + Radiotherapy arm
Description: Radiation Therapy in combination with Immunotherapy drug (Durvalumab)
Study: NCT04113837

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: food range
Description: The food range is comprised of:~sausages (1100 g per week) eggs (3 eggs per week), 100 g mushrooms per day, one bread per week, bread rolls, 100 ml ice cream per week, 3x 70 g pasta per week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: food range
Description: The food range is comprised of:~sausages (1100 g per week) eggs (3 eggs per week), 100 g mushrooms per day, one bread per week, bread rolls, 100 ml ice cream per week, 3x 70 g pasta per week
Study: NCT01685580

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manufacturer (VPAP ST)
Description: non-invasive ventilation in two pressure levels 7 days before surgery
Study: NCT03215979

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: 5 ml of saline 0.9%will be applied in the temporal fascia as a placebo used to compare to the experimental group.
Study: NCT04056156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV-screening advice
Description: To increase GP's HIV-testing behavior a targeted HIV-testing advice is spread to participants through an electronic mail

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV-screening advice
Description: To increase GP's HIV-testing behavior a targeted HIV-testing advice is spread to participants through an electronic mail

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV-testing advice plus group-level training
Description: To increase specific HIV-testing behavior among GPs a targeted HIV-testing advice is spread to participants through an electronic mail and an additional face-to-face group-level training is provided.
Study: NCT03197311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: A customized mobile application will be developed and downloaded to subjects; smartphones to monitor postoperative analgesic consumption, and disposal; pain control and patient satisfaction. The mobile app will provide notifications for medications and select education links on the prescribed analgesics. Subjects will receive reminders to take medications as directed. Subjects will be able to monitor and report their pain during the first week after surgery.
Study: NCT02275936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: S Nitrosoglutathione Reductase Inhibitor
Study: NCT04492722

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive once daily oral dose of placebo matched to AZD5718, and will continue until Week 20.
Study: NCT01863264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Thin Liquid Barium
Description: Cold thin liquid barium will be fed to the participant from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow)). For this study the refrigerated (cold) thin liquid barium will be measured for an exact temperature of 4-9°C prior to administration to control for any temperature variation. A total of 5 swallows will be visualized and saved electronically on the hospital's electronic storage system.
Study: NCT03126877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: The surgical procedure includes a low dose, short duration mitomycin C (MMC) treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: The surgical procedure includes a low dose, short duration mitomycin C (MMC) treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Raindrop Near Vision Inlay
Description: The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominante eye for the improvement of uncorrected near vision.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Raindrop Near Vision Inlay
Description: The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominante eye for the improvement of uncorrected near vision.
Study: NCT03538678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kwit smartphone app
Description: Kwit smarphone app
Study: NCT04533880

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBM
Description: Demineralized bone matrix (Allosync, CDMB Putty, Arthrex, Naples, FL)
Study: NCT00950612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational vaccine 692342
Description: Intramuscular injection, 2 doses
Study: NCT04533880

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium phosphate cement
Description: Quickset, Arthrex, Naples, FL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone graft
Description: Autologous bone grafting involves utilizing bone obtained from the same individual receiving the graft

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous bone graft
Description: Autologous bone grafting involves utilizing bone obtained from the same individual receiving the graft

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Autologous bone graft
Description: Autologous bone grafting involves utilizing bone obtained from the same individual receiving the graft
Study: NCT00950612

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection, 2 doses
Study: NCT02123017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 grams of Crystalline Lactulose
Description: 15 mg of bisacodyl, plus 30 grams crystalline lactulose x 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 135 grams of Crystalline Lactulose
Description: 15 mg of bisacodyl, plus 45 grams crystalline lactulose x 3 doses
Study: NCT02849665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Position
Study: NCT00185991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gentamicin
Description: Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).~Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gentamicin
Description: Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).~Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours).
Study: NCT04104529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: The biological collection will also include samples of blood samples collected before and during treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tumor collection
Description: Tumor collection (diagnosis) will be done for thyroid cancer and neuroencrine
Study: NCT03875118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The mouth-opening training with follow-up telephone calls program
Description: Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The mouth-opening training without follow-up telephone calls program
Description: Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
Study: NCT01799031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: internet-based intervention
Description: Receive access to the WISE web-based educational intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Receive standard of care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive access to the WISE web-based educational intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT02123017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 180 grams of Crystalline Lactulose
Description: 15 mg of bisacodyl, plus 60 grams crystalline lactulose x 3 doses